References
- Ansell B M. Scleroderma in Childhood. Systemic Sclerosis: scleroderma, M Jayson, IV, C M Black. John Wiley & Sons Ltd, London 1988; 319–29
- Silver R M, Le Roy E C. Immunological diseases. Systemic sclerosis (scleroderma), M Samter, D W Telmage, M M Frank, K F Austen, H N Klaman. Boston, Little, Brown 1988
- Masi A T, Rodnan G P, Medsger T A, jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 15: 581–90
- Le Roy E C, Black C, Fleishmajer R, et al. Scleroderma (systemic sclerosis): Classification, subset and pathogene-sis. J Rheumatol 1988; 15: 202–5
- Standardization of lung function tests. Bull Eur Physio-path Respir 1983; 19(Suppl 5): 1
- Silver R M, Metcalf J F, Stanley J H, Le Roy E C. Interstitial lung disease in scleroderma. Arthritis Rheum 1984; 27: 1254–61
- Matucci-Cerinic M, Pignone A, Iannone F, et al. Clinical correlations of angiotensin converting (ACE) plasmatic activity in systemic sclerosis. A longitudinal study of plasmatic ACE, endothelial injury and lung damage. Respir Med 1990; 84: 283–7
- Ghersetich I, Matucci-Cerinic M, Lotti T. The pathoge-netic treatment of systemic sclerosis (scleroderma). Int J Dermatol 1990; 29: 616–22
- Steen W D, Owens G R, Redniond C, et al. The effect of D-Penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28: 882–8
- Matucci-Cerinic M, Falcini F, Bartolozzi G, Volpi M. Nife-dipine treatment of Raynaud's phenomenon in pediatric age. Int J Clin Pharmacol Res 1985; 5: 67–9